Canadian radiotherapy device manufacturer Resonant Medical reported that it had raised $24 million Canadian ($20.7 million U.S.) in Series B financing.
The Montreal-based firm said that the latest financing round represents the largest venture capital investment raised by a private Canadian medical device company this year.
The company said it would use the funding to market its Restitu 3D ultrasound-guided radiation therapy platform for prostate cancer applications, and also to complete development on new products for head and neck, breast, and gynecological applications.
By AuntMinnie.com staff writers
December 15, 2005
Related Reading
Resonant gets 510(k), December 21, 2004
New financing for Resonant, October 7, 2004
Copyright © 2005 AuntMinnie.com